Burkitt's lymphoma : the prevalence of HIV/AIDS and the outcome of treatment by Hesseling, P. B. et al.
84       February 2018, Vol. 108, No. 2
IN PRACTICE
The population of Cameroon in 2014 was 22 773 014, of whom 
~40% (9 109 205) were aged <15 years. It was estimated that 94 000 
of these children (1%) were infected with HIV, and only 11% of these 
received antiretroviral (ARV) therapy.[1] In 2013, the prevalence of 
HIV infection in pregnant women in the north-west and south-west 
regions was 4.6% and 6.8%, respectively, and the mother-to-child 
transmission rate in 18-month-old breastfed infants was 25%.[1] 
Children diagnosed with Burkitt’s lymphoma (BL) between 2003 and 
2015 at Banso and Mbingo Baptist hospitals in the north-west and 
Mutengene Baptist Hospital in the south-west were all treated with 
cyclophosphamide-based chemotherapy regimens, with an overall 
long-term survival rate of 55%.[2]
Objective
To record the prevalence of HIV and the outcome of treatment in a 
large cohort of patients with BL.
Methods
Our database is a Pediatric Oncology Network Database (POND) 
cancer registry for the period 2003 - 2013. The number of patients 
in whom enzyme-linked immunosorbent assay was positive for 
HIV, the CD4+ count when available, and whether ARV treatment 
was given or not were extracted from the database. The diagnosis 
of BL was based on a fine-needle tumour aspirate, a bone marrow 
aspirate, a cytological cerebrospinal fluid examination and an 
abdominal ultrasound scan. The long-term outcome was established 
by personal follow-up of every HIV-positive patient or their families. 
Chemotherapy induction treatment consisted of cyclophos-
phamide (CPM) 40 mg/kg on days 1, 8 and 15, followed by 
consolidation chemotherapy with 1 - 3 more doses of CPM with or 
without intravenous (IV) vincristine 1.5 mg/m2 and IV metho trex-
ate 1.0  g/m2 for advanced or non-responsive disease. The duration 
of chemotherapy was 2 months. Rescue treatment of early relapses 
consisted of 3 weekly pulses of CPM and vincristine, and relapses 
beyond 1 year were treated in full again. [3] ARV treatment was not 
freely available in the early years of the study. More recent treatment 
always consisted of three drugs, based on World Health Organization 
guidelines and the national protocol. Examples of first-line treatment 
are as follows: age <3 years – abacavir  + lamivudine + lopinavir/
ritonavir; age 3 - 10 years and adolescents weighing <35 kg – 
abacavir + lamivudine + efavirenz; and age 11 - 19 years or weight 
>35 kg – tenofovir + lamivudine (or emtricitabine) + efavirenz.
Ethical approval for the BL treatment protocols was obtained from 
the Institutional Review Board of the Cameroon Baptist Convention 
Health Board.
Results
Of 979 patients diagnosed with BL, 717 (73.2%) were tested for 
HIV and 11 (1.5%) tested positive. Their ages ranged from 2 to 13 years 
(median 7 years). The age at diagnosis of BL, St Jude stage of the 
BL, CD4+ count if done, ARV treatment given, current status and 
duration of long-term survival are listed in Table 1. On 30 Octo-
ber 2016, three of eight patients (37.5%) who had received the 
recommended ARV treatment and were still on ARV maintenance 
treatment were long-term survivors at 111, 96 and 62 months, 
respectively. Three patients who were not treated with ARVs died 
within 3 - 15 months, and five patients treated with ARVs died 
within 3 - 39 months after the onset of treatment from progressive 
disease. There was no chemotherapy-related death. The CD4+ 
count at diagnosis was recorded in only four patients.
Discussion
Children with HIV have an increased risk of developing malignancies, 
and BL accounted for 21% of malignancies in HIV-positive children 
in South Africa, with a projected cure rate of 54.6% at 60 months 
using modern chemotherapy.[4] Modern chemotherapy for BL has 
a potential cure rate of >90% in HIV-negative patients,[5] but at 
considerable cost and the risk of significant morbidity. Our BL 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
HEALTHCARE DELIVERY
Burkitt’s lymphoma: The prevalence of HIV/AIDS  
and the outcome of treatment
P B Hesseling,1 MD; F Kouya,2 MD; E Katayi,2 MD; G Mbah,2 RN; P Wharin,3 MD
1  Department of Paediatrics and Child Health, Tygerberg Children’s Hospital and Faculty of Medicine and Health Sciences, Stellenbosch University, 
South Africa
2 Cameroon Baptist Convention Health Board, Bamenda, Cameroon
3 Beryl Thyer Memorial Africa Trust, Warkton, UK
Corresponding author: P B Hesseling (pbh@sun.ac.za)
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available treatment option for BL and was associated with 37.5% long-term survival in a resource-limited setting.
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patients were treated with chemotherapy of much lower intensity 
because of limited access to drugs and supportive care.[6] Long-term 
survival of 5 - 9 years in three of eight patients (37.5%) who received 
both chemotherapy and ARVs is encouraging. The documented 
HIV prevalence rate of 1.5% in this large cohort of BL patients is 
comparable to the 1% HIV prevalence rate for the general population 
of children in Cameroon.
Conclusion
HIV-positive children with BL are best treated with a context-
appropriate chemotherapy regimen.
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Table 1. Patient details and outcome
Patient no. Age (years) St Jude stage
CD4+ count 
(cells/µL) ARV treatment Current status
Length of 
survival  
(months)
1 5 III No record No Dead 15
2 12 III 145 Yes Dead 6
3 7 III No record Yes Alive 96
4 3 III 559 Yes Alive 111
5 9 III No record No Dead 3
6 2 III No record Yes Alive 62
7 4 II No record Yes Dead 4
8 3 III No record No Dead 3
9 8 III No record Yes Dead 39
10 12 IV 80 Yes Dead 39
11 13 III 30 Yes Dead 3
ARV = antiretroviral.
